

## SUPPLEMENTARY TABLE

Supplementary Table S1: Treatments for recurrent HGG

Treatment	Author (year)	Tumor Type	PFS-6 rate (%)	Median PFS (months)	Median OS (months)	Clinical Benefit (%) (CR+PR+SD)
<b>TMZ</b>	Perry et al. (2008) <sup>17</sup>	Recurrent GBM	17% (group 1, GBM) 57% (group 2, GBM)	N/A	N/A	47.3% (group 1) 78.6% (group 2)
	Perry et al. (2010) <sup>30</sup>	GBM with progression	23.9% (all) 27.3% (early) 7.4% (extended) 35.7% (rechallenge)	N/A 3.6 (early) 1.8 (extended) 3.7 (rechallenge)	N/A	N/A 27.3% (early) 7.7% (extended) 37.0% (rechallenge)
<b>Bevacizumab (BV)</b>						
BV	Kreisl et al. (2009) <sup>31</sup>	Recurrent GBM	29%	16 weeks	31 weeks	35% (CR+PR)
BV + CPT	Vredenburgh et al. (2007) <sup>32</sup>	Recurrent GBM	46%	24 weeks	42 weeks	57% (CR+PR)
	Gil et al. (2012) <sup>33</sup>	Recurrent MG	N/A 46% (GBM)	5.1 (all) 5.1 (GBM)	9 (all) 8.8 (GBM)	71% (all) 67.4% (GBM)
BV / BV + CPT	Friedman et al. (2009) <sup>18</sup>	Recurrent GBM in first or second relapse	42.6% (BV) 50.3% (BV+CPT)	4.2 (BV) 5.6 (BV+CPT)	9.2 (BV) 8.7 (BV+CPT)	28.2% (BV) 27.2% (BV+CPT) (CR+PR)
BV + CT	Norden et al. (2008) <sup>34</sup>	Recurrent MG	39% 42% (GBM)	23.5 weeks	35.7 weeks	93.2% (CR+PR+MR+SD)
BV + Nitrosourea	Soffiatti et al. (2009) <sup>35</sup>	Recurrent MG	N/A	N/A	N/A	35% (CR+PR)
BV + TMZ	Verhoeff et al. (2010) <sup>36</sup>	Recurrent HGG	17.4% (all) 6.7% (GBM)	13.9 weeks (all) 10.4 weeks (GBM)	17.1 weeks (all) 15.7 weeks (GBM)	20% (all) 16.7% (GBM) (CR+PR)
<b>Nitrosourea</b>						
Lomustine	Wick et al. (2010) <sup>37</sup>	Recurrent GBM	19.0%	1.6	7.1	40.2%
Fotemustine (FTM)	Paccapelo et al. (2012) <sup>38</sup>	Recurrent or progressive GBM	33.1% (All) 24% (early) 28.9% (extended) 31.3% (rechallenge)	N/A	N/A	47.9% (All) 45% (early) 36% (extended) 42.2% (rechallenge)
PCV	Brada et al. (2010) <sup>39</sup>	Recurrent HGG	N/A	3.6	6.7	-
<b>NovoTTF-100A</b>	Stupp et al. (2012) <sup>40</sup>	Recurrent GBM	21.4%	2.2	6.6	14% (CR+PR)

Abbreviation: PFS, progression-free survival; PFS-6, 6-month progression-free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; MR, minimal response; MG, malignant gliomas; GBM, glioblastoma; HGG, high grade glioma; TMZ, temozolomide; BV, bevacizumab; CT, chemotherapy; FTM, fotemustine; TTF, tumour treating fields; PCV, procarbazine + lomustine + vincristine; N/A, data not available.